Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: An indirect mixed treatment comparison meta-analysis

BMJ Supportive and Palliative Care

Volumn 2, Issue 2, 2012, Pages 156-162

  Jandhyala, Ravi ^a   Fullarton, John ^b  

^a Cephalon UK Ltd   (United Kingdom)

^b 'Strategen   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; BREAKTHROUGH PAIN; COMPLICATION; DRUG EFFECTS; FEMALE; HUMAN; MALE; MEDICINAL CHEMISTRY; META ANALYSIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM; PAIN MEASUREMENT; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; ADULT; AGED; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; CHEMISTRY, PHARMACEUTICAL; COMBINED MODALITY THERAPY; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN MEASUREMENT;

EID: 84884729374     PISSN: 2045435X     EISSN: 20454368     Source Type: Journal    
DOI: 10.1136/bmjspcare-2011-000139     Document Type: Article

References (42)

1. Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009;20:1420-1433.
2. Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician offi ce visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002;3:38-44.
3. Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13:331-338.
4. Portenoy RK, Bruns D, Shoemaker B, et al. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of life. J Opioid Manag 2010;6:109-116.
5. Greco MT, Corli O, Montanari M, et al. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. Clin J Pain 2011;27:9-18.
6. Fortner BV, Demarco G, Irving G, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage 2003;25:9-18.
7. Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care 2009;3:1-6.
8. Hagelberg NM, Olkkola KT. Fentanyl for breakthrough cancer pain-what's new? Pain 2010;151:565-566.
9. Portenoy RK, Hagen NA. Breakthrough pain: defi nition, prevalence and characteristics. Pain 1990;41:273-281.
10. Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805-811.
11. Slatkin NE, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;5:327-334.
12. Rauck RL, Tark M, Reyes E, et al. Effi cacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009;25:2877-2885.
13. Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998;90:611-616.
14. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release (MSIR). Pain 2001;91:123-130.
15. Effentora Summary of Product Characteristics. Cephalon UK, Welwyn Garden City, UK, 2010.
16. Abstral Sublingual Tablets Summary of Product Characteristics. ProStrakan, Galashiels, UK, 2010.
17. Actiq Summary of Product Characteristics. Flynn Pharma, Dublin, Ireland, 2010.
18. Sutton A, Ades AE, Cooper N, et al. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008;26:753-767.
19. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900.
20. Vissers D, Stam W, Nolte T, et al. Effi cacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin 2010;26:1037-1045.
21. Mills EJ, Druyts E, Ghement I, et al. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol 2011;3:107-129.
22. Phung OJ, Kahn SR, Cook DJ, et al. Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. Chest 2011;140:374-381.
23. Blanchard P, Hill C, Guihenneuc-Jouyaux C, et al. Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. J Clin Epidemiol 2011;64:985-992.
24. Maund E, McDaid C, Rice S, et al. Paracetamol and selective and non-selective nonsteroidal anti-infl ammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review. Br J Anaesth 2011;106:292-297.
25. Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010;303:1410-1418.
26. Van den Bruel A, Gailly J, Devriese S, et al. The protective effect of ophthalmic viscoelastic devices on endothelial cell loss during cataract surgery: a meta-analysis using mixed treatment comparisons. Br J Ophthalmol 2011;95:5-10.
27. Bansback N, Sizto S, Sun H, et al. Effi cacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology (Basel) 2009;219:209-218.
28. Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769-1781.
29. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drugeluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-948.
30. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. June 2008. www.nice.org.uk/ (Accessed May 2011).
31. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. BMJ 2003;327:557-560.
32. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006;11:193-206.
33. Lunn DJ, Thomas A, Best N, et al. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 2000;10:325-337.
34. MRC Biostatistics Unit, Cambridge, UK. The BUGS project. www.mrc-bsu.cam.ac.uk/bugs/ (Accessed 18 May 2011).
35. Gómez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage 2002;24:45-52.
36. Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets: enhanced buccal absorption. Am J Drug Deliv 2006;4:1-5.
37. Pather SI, Siebert JM, Hontz j, et al. Enhanced buccal delivery of fentanyl using the OraVescent drug delivery system. Drug Delivery Tech 2001;1:54-57.
38. Collins SL, Faura CC, Moore RA, et al. Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage 1998;16:388-402.
39. Cephalon UK. Clinical Study Report: Study No. 9914. Welwyn Garden City, UK, 2005.
40. Cephalon UK. Clinical Study Report: Study No. 3039. Welwyn Garden City, UK, 2007
41. Cephalon UK. Study Summary Report. AC 200/013. Welwyn Garden City, UK, 1999.
42. Cephalon UK. Study Summary Report. AC 600/001. Welwyn Garden City, UK, 1999.